Rhythm Pharma Secures FDA Approval for IMCIVREE in Acquired Obesity
Mar 20, 2026 (20 hr ago)
Positive
FDA approved IMCIVREE for acquired hypothalamic obesity, immediately available in the U.S. targeting an estimated 10,000 patients.
FDA Approval and Clinical Efficacy
- The FDA expanded IMCIVREE (setmelanotide) indication to treat acquired hypothalamic obesity (HO) patients.1
- Approval rests on positive Phase 3 TRANSCEND trial data showing a -18.4% placebo-adjusted BMI reduction versus placebo.4
Market Potential and Immediate Access
- Rhythm estimates the U.S. market for acquired HO comprises approximately 10,000 individuals, representing a significant opportunity.2
- The drug is immediately available for patients across the U.S. following the regulatory decision.3
Operational Support and Strategy
- The company is launching its InTune program to provide personalized educational support for individuals living with these rare obesity forms.3
- Rhythm commits to working closely with payers and other stakeholders to ensure broad patient access to the newly approved therapy.5
